Chen B, Dong J, Ruelas M, Ye X, He J, Yao R, Fu Y, Liu Y, Hu J, Wu T, et al
Medical review is included, but the program is streamlined by design
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss and cardiometabolic outcomes compared to GLP-1 agonists alone
ORIGIN Trial Investigators
Most people report noticing appetite reduction and mild weight changes by the end of week two, with more substantial results visible after 812 weeks of consistent treatment
And recently it exploded across mainstream social media perhaps most notably after Andrew Huberman said on TBPN that this could be a trillion-dollar drug because of the dramatic weight loss and some degree of muscle sparing . *Authors note: Andrew and I are on good terms, and everyone misspeaks from time to time myself included